Adhera Therapeutics, Inc.
ATRX
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.28M | 1.56M | 1.71M | 1.62M | 1.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.28M | 1.56M | 1.71M | 1.62M | 1.46M |
| Operating Income | -1.28M | -1.56M | -1.71M | -1.62M | -1.46M |
| Income Before Tax | -4.49M | -2.75M | -2.93M | -2.11M | -3.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.49 | -2.75 | -2.93 | -2.11 | -3.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.49M | -2.75M | -2.93M | -2.11M | -3.45M |
| EBIT | -1.28M | -1.56M | -1.71M | -1.62M | -1.46M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.16 | -0.91 | -1.25 | -1.47 | -3.74 |
| Normalized Basic EPS | -0.73 | -0.59 | -0.69 | -0.56 | -1.74 |
| EPS Diluted | -1.25 | -0.99 | -1.25 | -1.47 | -3.74 |
| Normalized Diluted EPS | -0.77 | -0.63 | -0.69 | -0.56 | -1.74 |
| Average Basic Shares Outstanding | 14.11M | 12.97M | 10.65M | 8.33M | 6.02M |
| Average Diluted Shares Outstanding | 109.19M | 108.05M | 10.65M | 8.33M | 6.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
